MHT may increase chance of reflux by a third in postmenopausal women
There’s a significant link between oestrogen, progestogen and combined hormone therapy with gastr-oesophageal reflux disease.
Use of menopausal hormone therapy is associated with increased risk of gastro-oesophageal reflux disease among postmenopausal women, according to a review in Menopause.
US clinicians conducted a systematic review and meta-analysis to examine the association between ever or current menopausal hormone therapy (MHT) use and gastro-oesophageal reflux disease (GORD).
Overall, the researchers observed a 29% higher risk of GORD among women who used MHT.
They also found a 41%, 39% and 16% elevated risk with oestrogen-only, progesterone-only and combination therapy, respectively.
